Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy,
resulting in considerable undertreatment or overtreatment. New insights into the role of …

Background The sensitivity and specificity of minimal residual disease detected by
circulating tumor DNA profiling (ctDNA MRD) in lung cancer, with particular attention to the …

Background Precision therapy for lung cancer will require comprehensive genomic testing to
identify actionable targets as well as ascertain disease prognosis. RNA-seq is a robust …

Background Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA
NSCLC, after surgical resection remains unclear. We aimed to compare the effect of …

Purpose: New prognostic markers to guide treatment decisions in early stage non–small cell
lung cancer are necessary to improve patient outcomes. In this report, we assess the utility of …

Background Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive
tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in …

Introduction Many early stage non–small-cell lung cancer (NSCLC) patients who are not
considered candidates for adjuvant treatment according to current guidelines do harbor …

Background and Goals. To identify a multigene signature model for prognosis of non‐small‐
cell lung cancer (NSCLC) patients, we first found 2146 consensus differentially expressed …

Non-small cell lung cancer (NSCLC) is a heterogeneity disease and to date, specific clinical
factors and tumor stage are established as prognostic markers. Nevertheless, prognosis …

Background Recent studies have suggested that more frequent postoperative surveillance
imaging via computed tomography following lung cancer resection may not improve …